Proton pump inhibitors (PPIs) are frequently recommended for the management of gastroesophageal reflux disease (GERD) and peptic ulcers. This review article dwells upon various adverse effects that are associated with the extended use of PPIs and the mechanisms by which the PPIs lead to the progression of these complications, including Clostridium difficile infection (CDI) and pneumonia that develops due to impaired absorption caused by hypochlorhydria; cognitive impairment through decreased clearance of amyloid beta peptide and reduced synthesis of acetylcholine; osteoporosis that progresses due to reduced calcium absorption and disrupted bone remodeling through the effects on TRPM6/7 channels; Chronic kidney disease (CKD) caused by acute interstitial nephritis and vascular calcifications brought by hypomagnesemia; metabolic syndrome and type 2 Diabetes Mellitus. As such, clinicians must exercise carefulness when prescribing PPIs for extended periods. The most important aspect is the careful assessment of the indication prior to commencing the treatment, as well as reassessing the indication throughout its long-term administration.

In February 2025, we are very pleased to interview Professor Robert Peter Gale, Editor-in-Chief of Leukemia. Prof. Gale has dedicated to scientific and clinical research on leukemia and other bone marrow disorders over 50 years. In this interview, Prof. Gale shared his views on AI technology and its impact on the development of hematology.

A research team led by Haruyo Yamamoto, Chisa Nakashima, and Atsushi Otsuka from Department of Dermatology, Kindai University Faculty of Medicine, in collaboration with the Faculty of Engineering at Kindai University and other institutions, has developed a diagnostic system that uses artificial intelligence (AI) to accurately identify the type of facial pigmented lesions and support laser treatment decisions. A paper on this study was published online in Cureus, an international medical journal on June 5, 2025.

Current protective clothing often lacks sufficient comfort to ensure efficient performance of healthcare workers. Developing protective textiles with high air and moisture permeability is a potential and effective solution to discomfort of medical protective clothing. However, realizing the facile production of a protective textile that combines safety and comfort remains a challenge. Herein, we report the fabrication of highly permeable protective textiles (HPPT) with micro/nano-networks, using non-solvent induced phase separation synergistically driven by CaCl₂ and fluorinated polyurethane, combined with spraying technique. The HPPT demonstrates excellent liquid repellency and comfort, ensuring high safety and a dry microenvironment for the wearer. The textile exhibits not only a high hydrostatic pressure (12.86 kPa) due to its tailored small mean pore size (1.03 μm) and chemical composition, but also demonstrates excellent air permeability (14.24 mm s⁻¹) and moisture permeability (7.92 kg m⁻² d⁻¹) owing to the rational combination of small pore size and high porosity (69%). The HPPT offers superior comfort compared to the commercially available protective materials. Additionally, we elucidated a molding mechanism synergistically inducted by diffusion-dissolution-phase separation. This research provides an innovative perspective on enhancing the comfort of medical protective clothing and offers theoretical support for regulating of pore structure during phase separations.

The review highlights how disrupting the cell cycle, a process often hijacked by cancer cells for unchecked growth offers a promising strategy for cancer therapy. It focuses on drugs that precisely target key cell cycle regulators, several of which are already in clinical use. By showcasing the latest breakthroughs and outlining future research directions, the article provides a comprehensive look at how targeting cell cycle dysregulation is shaping the future of cancer care.